Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” in the peer-reviewed scientific journal Journal of Hepatology. The study describes the pre-clinical research developed in collaboration with Inventiva, a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of NASH and other diseases with unmet medical need.

“The study demonstrates the beneficial effects of the pan-PPAR agonist lanifibranor improving the phenotype of liver sinusoidal endothelial cells, hepatic stellate cells and hepatic macrophages, which ultimately lead to reduction in portal pressure and hepatic fibrosis. Data derives from two pre-clinical models of advanced chronic liver disease and human primary cells cultured in the ExoLiver® platform” summarize Zoe Boyer-Díaz and Peio Aristu-Zabalza, Associate Scientists at BLB and co-first authors of the manuscript. “Considering the lack of treatments for advanced chronic liver disease, and its most deleterious complication portal hypertension, the findings included in this manuscript shed light on the way to develop novel therapies for patients with chronic hepatopathies” added Dr Jordi Gracia-Sancho, CSO and co-founder of BLB.

“We are very pleased to see our latest preclinical results on lanifibranor for the treatment of cirrhosis published in the renowned Journal of Hepatology. This scientific paper, smartly developed by BLB, clearly illustrates that lanifibranor significantly improves key features of this severe disease. These beneficial effects are based on lanifibranor’s capacity to target all three PPAR isoforms concomitantly” stated Pierre Broqua, CSO and co-founder of Inventiva.

View full article

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Liver Diseases. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.